We have located links that may give you full text access.
English Abstract
Journal Article
Review
[Journey of the S‑ICD to first-line therapy].
The subcutaneous implantable cardioverter-defibrillator (S-ICD®, Boston Scientific, Marlborough, MA, USA, previously Cameron Health, San Clemente, CA, USA) represents an important milestone in ICD therapy for prevention of sudden cardiac death (SCD). Since the introduction of the S‑ICD in 2010, the device has undergone further development. Based on the unique feature of an entirely extracardiac implantation, the S‑ICD is able to reduce the common perioperative and long-term complications of the usual endovascular implanted ICD systems. Especially for patients with a complex anatomy and no option of an endovascular lead implantation, the S‑ICD offers a potential alternative. Regarding the initial uncertainty if this innovative ICD approach is actually reliable in detecting and terminating ventricular arrhythmias has been resolved by multiple clinical studies and trials providing evidence for an effective treatment. Based on the obvious advantages compared to conventional ICD systems, the question arises if the S‑ICD should actually be the first choice in the majority of all primary prevention patients in the future. Furthermore, recent data from large registries show that S‑ICD indications are also expanding in secondary prevention patients. As a consequence the S‑ICD was listed in the 2015 ESC guidelines as an alternative therapeutic option with a class IIa recommendation in patients with an ICD indication not requiring pacing for bradycardia, cardiac resynchronization therapy or anti-tachycardia pacing (ATP). In addition, the American Heart Association guidelines refer to class I recommendation for patients with a complex anatomy and venous access problems or at a high risk for infections who need ICD therapy. Limitations with respect to the not available pacing option of S‑ICD might be also overcome by a potential combination with a leadless pacemaker in the near future. This article provides an overview of recent developments of the S‑ICD and reviews the most recent literature and ongoing studies.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app